CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: prostate cancer markers</title> <meta name="description" content="Search results for: prostate cancer markers"> <meta name="keywords" content="prostate cancer markers"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="prostate cancer markers" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="prostate cancer markers"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 2827</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: prostate cancer markers</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2827</span> The Role of Genetic Markers in Prostate Cancer Diagnosis and Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Farman%20Ali">Farman Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Asif%20Mahmood"> Asif Mahmood</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The utilization of genetic markers in prostate cancer management represents a significant advance in personalized medicine, offering the potential for more precise diagnosis and tailored treatment strategies. This paper explores the pivotal role of genetic markers in the diagnosis and treatment of prostate cancer, emphasizing their contribution to the identification of individual risk profiles, tumor aggressiveness, and response to therapy. By integrating current research findings, we discuss the application of genetic markers in developing targeted therapies and the implications for patient outcomes. Despite the promising advancements, challenges such as accessibility, cost, and the need for further validation in diverse populations remain. The paper concludes with an outlook on future directions, underscoring the importance of genetic markers in revolutionizing prostate cancer care. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title="prostate cancer">prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=genetic%20markers" title=" genetic markers"> genetic markers</a>, <a href="https://publications.waset.org/abstracts/search?q=personalized%20medicine" title=" personalized medicine"> personalized medicine</a>, <a href="https://publications.waset.org/abstracts/search?q=BRCA1%20and%20BRCA2" title=" BRCA1 and BRCA2"> BRCA1 and BRCA2</a> </p> <a href="https://publications.waset.org/abstracts/184866/the-role-of-genetic-markers-in-prostate-cancer-diagnosis-and-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/184866.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">65</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2826</span> Early Cell Cultures Derived from Human Prostate Cancer Tissue Express Tissue-Specific Epithelial and Cancer Markers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vladimir%20Ryabov">Vladimir Ryabov</a>, <a href="https://publications.waset.org/abstracts/search?q=Mikhail%20Baryshevs"> Mikhail Baryshevs</a>, <a href="https://publications.waset.org/abstracts/search?q=Mikhail%20Voskresenskey"> Mikhail Voskresenskey</a>, <a href="https://publications.waset.org/abstracts/search?q=Boris%20Popov"> Boris Popov</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The human prostate gland (PG) samples were obtained from patients who had undergone radical prostatectomy for prostate cancer (PC) and used to extract total RNA and prepare the prostate stromal cell cultures (PSCC) and patients-derived organoids (PDO). Growth of the cell cultures was accessed under microscopic evaluation in transmitted light and the marker expression by reverse polymerase chain reaction (RT-PCR), immunofluorescence, and immunoblotting. Some PCR products from prostate tissue, PSCC, and PDO were cloned and sequenced. We found that the cells of early and late passages of PSCC and corresponding PDO expressed luminal (androgen receptor, AR; cytokeratin 18, CK18) and basal (CK5, p63) epithelial markers, the production of which decreased or disappeared in late PSCC and PDO. The PSCC and PDO of early passages from cancer tissue additionally produced cancer markers AMACR, TMPRSS2-ERG, and Ezh2. The expression of TMPRSS2-ERG fusion transcripts was verified by cloning and sequencing the PCR products. The results obtained suggest that early passages of PSCC might be used as a pre-clinical model for the evaluation of early markers of prostate cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=localized%20prostate%20cancer" title="localized prostate cancer">localized prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20epithelial%20markers" title=" prostate epithelial markers"> prostate epithelial markers</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers" title=" prostate cancer markers"> prostate cancer markers</a>, <a href="https://publications.waset.org/abstracts/search?q=AMACR" title=" AMACR"> AMACR</a>, <a href="https://publications.waset.org/abstracts/search?q=TMPRSS2-ERG" title=" TMPRSS2-ERG"> TMPRSS2-ERG</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20stromal%20cell%20cultures" title=" prostate stromal cell cultures"> prostate stromal cell cultures</a>, <a href="https://publications.waset.org/abstracts/search?q=PDO" title=" PDO"> PDO</a> </p> <a href="https://publications.waset.org/abstracts/153032/early-cell-cultures-derived-from-human-prostate-cancer-tissue-express-tissue-specific-epithelial-and-cancer-markers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153032.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">110</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2825</span> Clinical Relevance of TMPRSS2-ERG Fusion Marker for Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shalu%20Jain">Shalu Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=Anju%20Bansal"> Anju Bansal</a>, <a href="https://publications.waset.org/abstracts/search?q=Anup%20Kumar"> Anup Kumar</a>, <a href="https://publications.waset.org/abstracts/search?q=Sunita%20Saxena"> Sunita Saxena</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: The novel TMPRSS2:ERG gene fusion is a common somatic event in prostate cancer that in some studies is linked with a more aggressive disease phenotype. Thus, this study aims to determine whether clinical variables are associated with the presence of TMPRSS2:ERG-fusion gene transcript in Indian patients of prostate cancer. Methods: We evaluated the clinical variables with presence and absence of TMPRSS2:ERG gene fusion in prostate cancer and BPH association of clinical patients. Patients referred for prostate biopsy because of abnormal DRE or/and elevated sPSA were enrolled for this prospective clinical study. TMPRSS2:ERG mRNA copies in samples were quantified using a Taqman chemistry by real time PCR assay in prostate biopsy samples (N=42). The T2:ERG assay detects the gene fusion mRNA isoform TMPRSS2 exon1 to ERG exon4. Results: Histopathology report has confirmed 25 cases as prostate cancer adenocarcinoma (PCa) and 17 patients as benign prostate hyperplasia (BPH). Out of 25 PCa cases, 16 (64%) were T2: ERG fusion positive. All 17 BPH controls were fusion negative. The T2:ERG fusion transcript was exclusively specific for prostate cancer as no case of BPH was detected having T2:ERG fusion, showing 100% specificity. The positive predictive value of fusion marker for prostate cancer is thus 100% and the negative predictive value is 65.3%. The T2:ERG fusion marker is significantly associated with clinical variables like no. of positive cores in prostate biopsy, Gleason score, serum PSA, perineural invasion, perivascular invasion and periprostatic fat involvement. Conclusions: Prostate cancer is a heterogeneous disease that may be defined by molecular subtypes such as the TMPRSS2:ERG fusion. In the present prospective study, the T2:ERG quantitative assay demonstrated high specificity for predicting biopsy outcome; sensitivity was similar to the prevalence of T2:ERG gene fusions in prostate tumors. These data suggest that further improvement in diagnostic accuracy could be achieved using a nomogram that combines T2:ERG with other markers and risk factors for prostate cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title="prostate cancer">prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=genetic%20rearrangement" title=" genetic rearrangement"> genetic rearrangement</a>, <a href="https://publications.waset.org/abstracts/search?q=TMPRSS2%3AERG%20fusion" title=" TMPRSS2:ERG fusion"> TMPRSS2:ERG fusion</a>, <a href="https://publications.waset.org/abstracts/search?q=clinical%20variables" title=" clinical variables"> clinical variables</a> </p> <a href="https://publications.waset.org/abstracts/8830/clinical-relevance-of-tmprss2-erg-fusion-marker-for-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/8830.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">444</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2824</span> The Many Faces of Cancer and Knowing When to Say Stop</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Diwei%20Lin">Diwei Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Amanda%20Jh.%20Tan"> Amanda Jh. Tan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We present a very rare case of de novo large cell neuroendocrine carcinoma of the prostate (LCNEC) in an 84-year-old male on a background of high-grade, muscle-invasive transitional cell carcinoma of the bladder. While NE tumours account for 1% to 5% of all cases of prostate cancer and scattered NE cells can be found in 10% to 100% of prostate adenocarcinomas, pure LCNEC of the prostate is extremely rare. Most LCNEC of the prostate is thought to originate by clonal progression under the selection pressure of therapy and refractory to long-term hormonal treatment for adenocarcinoma of the prostate. De novo LCNEC is only described in case reports and is thought to develop via direct malignant transformation. Limited data in the English literature makes it difficult to accurately predict the prognosis of LCNEC of the prostate. However, current evidence suggesting that increasing NE differentiation in prostate adenocarcinoma is associated with a higher stage, high-grade disease, and a worse prognosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=large%20cell%20neuroendocrine%20cancer" title="large cell neuroendocrine cancer">large cell neuroendocrine cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=refractory%20cancer" title=" refractory cancer"> refractory cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20and%20health%20sciences" title=" medical and health sciences"> medical and health sciences</a> </p> <a href="https://publications.waset.org/abstracts/10859/the-many-faces-of-cancer-and-knowing-when-to-say-stop" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/10859.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">422</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2823</span> Non-Signaling Chemokine Receptor CCRL1 and Its Active Counterpart CCR7 in Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yiding%20Qu">Yiding Qu</a>, <a href="https://publications.waset.org/abstracts/search?q=Svetlana%20V.%20Komarova"> Svetlana V. Komarova</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chemokines acting through their cognate chemokine receptors guide the directional migration of the cell along the chemokine gradient. Several chemokine receptors were recently identified as non-signaling (decoy), based on their ability to bind the chemokine but produce no measurable signal in the cell. The function of these decoy receptors is not well understood. We examined the expression of a decoy receptor CCRL1 and a signaling receptor that binds to the same ligands, CCR7, in prostate cancer using publically available microarray data (www.oncomine.org). The expression of both CCRL1 and CCR7 increased in an approximately half of prostate carcinoma samples and the majority of metastatic cancer samples compared to normal prostate. Moreover, the expression of CCRL1 positively correlated with the expression of CCR7. These data suggest that CCR7 and CCRL1 can be used as clinical markers for the early detection of transformation from carcinoma to metastatic cancer. In addition, these data support our hypothesis that the non-signaling chemokine receptors actively stimulate cell migration. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bioinformatics" title="bioinformatics">bioinformatics</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20migration" title=" cell migration"> cell migration</a>, <a href="https://publications.waset.org/abstracts/search?q=decoy%20receptor" title=" decoy receptor"> decoy receptor</a>, <a href="https://publications.waset.org/abstracts/search?q=meta-analysis" title=" meta-analysis"> meta-analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/23226/non-signaling-chemokine-receptor-ccrl1-and-its-active-counterpart-ccr7-in-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23226.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">473</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2822</span> Histopathological Characterization of Prostate Cancer in Saudi Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nadeem%20A.%20Kizilbash">Nadeem A. Kizilbash</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study aimed to compare the histopathological characterization of prostate cancer using the conventional and 2005 ISUP modified Gleason system. It employed samples from 40 prostate cancer patients employing resection, biopsies and RP. The majority of cases (95%) comprised adenocarcinoma of the prostate. The results showed that there is migration or upgrading of scores to higher values on using the 2005 ISUP modified Gleason system and an increase in a score of 7 in more than 45% of the cases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title="prostate cancer">prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=conventional%20gleason%20grading" title=" conventional gleason grading"> conventional gleason grading</a>, <a href="https://publications.waset.org/abstracts/search?q=2005%20ISUP%20modified%20gleason%20system" title=" 2005 ISUP modified gleason system"> 2005 ISUP modified gleason system</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathology" title=" histopathology"> histopathology</a> </p> <a href="https://publications.waset.org/abstracts/19268/histopathological-characterization-of-prostate-cancer-in-saudi-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/19268.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">428</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2821</span> Six Tropical Medicinal Plants Effects in the Treatment of Prostate Diseases in Forty Different Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=T.%20Nalowa">T. Nalowa</a>, <a href="https://publications.waset.org/abstracts/search?q=L.%20Foncha"> L. Foncha</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Eposi"> S. Eposi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate enlargement, prostate cancer are major global health problems affecting many men as they advance in age. It is highly recommended to encourage older men to get Prostate Specific Antigen test screening frequently. Conventional treatments like radiation, chemotherapy are associated with many side effects. And this situation is a call for concern. Traditional medicine is affordable, easily prepared with little or no side effects and it contains many phytochemicals. The study aims to find the cure for prostate cancer and prostate enlargement by extracting products from plant tissues of specific herbs to determine anti-inflammatory, anti-cancer, and anti-hematuria properties. Descriptive statistical analysis was applied to describe the data process. The commonly used method of preparation was extraction. Overall, 40 patients were classified based on their medical conditions on their underlying user report. Rural communities in Fako are rich sources of plants with medicinal properties. The used plants consequently provide basic information and aid to investigate the cure of prostate cancer and prostate enlargement, with great significance. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=enlargement" title=" enlargement"> enlargement</a>, <a href="https://publications.waset.org/abstracts/search?q=metastases" title=" metastases"> metastases</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate" title=" prostate"> prostate</a> </p> <a href="https://publications.waset.org/abstracts/177647/six-tropical-medicinal-plants-effects-in-the-treatment-of-prostate-diseases-in-forty-different-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/177647.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">75</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2820</span> Importance of Prostate Volume, Prostate Specific Antigen Density and Free/Total Prostate Specific Antigen Ratio for Prediction of Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aliseydi%20Bozkurt">Aliseydi Bozkurt</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: Benign prostatic hyperplasia (BPH) is the most common benign disease, and prostate cancer (PC) is malign disease of the prostate gland. Transrectal ultrasound-guided biopsy (TRUS-bx) is one of the most important diagnostic tools in PC diagnosis. Identifying men at increased risk for having a biopsy detectable prostate cancer should consider prostate specific antigen density (PSAD), f/t PSA Ratio, an estimate of prostate volume. Method: We retrospectively studied 269 patients who had a prostate specific antigen (PSA) score of 4 or who had suspected rectal examination at any PSA level and received TRUS-bx between January 2015 and June 2018 in our clinic. TRUS-bx was received by 12 experienced urologists with 12 quadrants. Prostate volume was calculated prior to biopsy together with TRUS. Patients were classified as malignant and benign at the end of pathology. Age, PSA value, prostate volume in transrectal ultrasonography, corpuscle biopsy, biopsy pathology result, the number of cancer core and Gleason score were evaluated in the study. The success rates of PV, PSAD, and f/tPSA were compared in all patients and those with PSA 2.5-10 ng/mL and 10.1-30 ng/mL tp foresee prostate cancer. Result: In the present study, in patients with PSA 2.5-10 ng/ml, PV cut-off value was 43,5 mL (n=42 < 43,5 mL and n=102 > 43,5 mL) while in those with PSA 10.1-30 ng/mL prostate volüme (PV) cut-off value was found 61,5 mL (n=31 < 61,5 mL and n=36 > 61,5 mL). Total PSA values in the group with PSA 2.5-10 ng/ml were found lower (6.0 ± 1.3 vs 6.7 ± 1.7) than that with PV < 43,5 mL, this value was nearly significant (p=0,043). In the group with PSA value 10.1-30 ng/mL, no significant difference was found (p=0,117) in terms of total PSA values between the group with PV < 61,5 mL and that with PV > 61,5 mL. In the group with PSA 2.5-10 ng/ml, in patients with PV < 43,5 mL, f/t PSA value was found significantly lower compared to the group with PV > 43,5 mL (0.21 ± 0.09 vs 0.26 ± 0.09 p < 0.001 ). Similarly, in the group with PSA value of 10.1-30 ng/mL, f/t PSA value was found significantly lower in patients with PV < 61,5 mL (0.16 ± 0.08 vs 0.23 ± 0.10 p=0,003). In the group with PSA 2.5-10 ng/ml, PSAD value in patients with PV < 43,5 mL was found significantly higher compared to those with PV > 43,5 mL (0.17 ± 0.06 vs 0.10 ± 0.03 p < 0.001). Similarly, in the group with PSA value 10.1-30 ng/mL PSAD value was found significantly higher in patients with PV < 61,5 mL (0.47 ± 0.23 vs 0.17 ± 0.08 p < 0.001 ). The biopsy results suggest that in the group with PSA 2.5-10 ng/ml, in 29 of the patients with PV < 43,5 mL (69%) cancer was detected while in 13 patients (31%) no cancer was detected. While in 19 patients with PV > 43,5 mL (18,6%) cancer was found, in 83 patients (81,4%) no cancer was detected (p < 0.001). In the group with PSA value 10.1-30 ng/mL, in 21 patients with PV < 61,5 mL (67.7%) cancer was observed while only in10 patients (32.3%) no cancer was seen. In 5 patients with PV > 61,5 mL (13.9%) cancer was found while in 31 patients (86.1%) no cancer was observed (p < 0.001). Conclusions: Identifying men at increased risk for having a biopsy detectable prostate cancer should consider PSA, f/t PSA Ratio, an estimate of prostate volume. Prostate volume in PC was found lower. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title="prostate cancer">prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20volume" title=" prostate volume"> prostate volume</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20specific%20antigen" title=" prostate specific antigen"> prostate specific antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=free%2Ftotal%20PSA%20ratio" title=" free/total PSA ratio"> free/total PSA ratio</a> </p> <a href="https://publications.waset.org/abstracts/99812/importance-of-prostate-volume-prostate-specific-antigen-density-and-freetotal-prostate-specific-antigen-ratio-for-prediction-of-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/99812.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2819</span> Using Self Organizing Feature Maps for Automatic Prostate Segmentation in TRUS Images</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ahad%20Salimi">Ahad Salimi</a>, <a href="https://publications.waset.org/abstracts/search?q=Hassan%20Masoumi"> Hassan Masoumi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate cancer is one of the most common recognized cancers in men, and, is one of the most important mortality factors of cancer in this group. Determining of prostate’s boundary in TRUS (Transrectal Ultra Sound) images is very necessary for prostate cancer treatments. The weakness edges and speckle noise make the ultrasound images inherently to segment. In this paper a new automatic algorithm for prostate segmentation in TRUS images proposed that include three main stages. At first morphological smoothing and sticks filtering are used for noise removing. In second step, for finding a point in prostate region, SOFM algorithm is enlisted and in the last step, the boundary of prostate extracting accompanying active contour is employed. For validation of proposed method, a number of experiments are conducted. The results obtained by our algorithm show the promise of the proposed algorithm. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=SOFM" title="SOFM">SOFM</a>, <a href="https://publications.waset.org/abstracts/search?q=preprocessing" title=" preprocessing"> preprocessing</a>, <a href="https://publications.waset.org/abstracts/search?q=GVF%20contour" title=" GVF contour"> GVF contour</a>, <a href="https://publications.waset.org/abstracts/search?q=segmentation" title=" segmentation"> segmentation</a> </p> <a href="https://publications.waset.org/abstracts/29731/using-self-organizing-feature-maps-for-automatic-prostate-segmentation-in-trus-images" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/29731.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">330</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2818</span> Serological Screening of Cytomegalovirus Infection among Sudanese Patients with Leukemia, Breast and Prostate Cancers at Radiation-Isotope Center in Khartoum</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abuelquasim.%20M.%20Hassan">Abuelquasim. M. Hassan</a>, <a href="https://publications.waset.org/abstracts/search?q=Namarig%20.S.%20Mohammed"> Namarig .S. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Samah%20F.%20Mohammed"> Samah F. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafaa.%20A.%20Mohammed"> Wafaa. A. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafaa%20M.%20Edriss"> Wafaa M. Edriss</a>, <a href="https://publications.waset.org/abstracts/search?q=Amel%20A.%20Ahmed"> Amel A. Ahmed</a>, <a href="https://publications.waset.org/abstracts/search?q=Elfadil%20M.%20Abass"> Elfadil M. Abass</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Cytomegalovirus (CMV), a common virus, usually causes asymptomatic infections in immunocompetent hosts; however, it may lead to serious complications especially in cancer patients. Objectives: This study was conducted to determine the seroprevalence of human cytomegalovirus (HCMV) among leukemia, breast and prostate cancer patients attending at Radiation Isotope-Center-Khartoum (RICK) from April to August 2016. Material and Methods: A total of 91 subjects were included: 30 leukemic, 22 breast cancer and 29 prostate cancer patients.10 of them were healthy and used as control group, serum samples were collected and tested for CMV IgG & IgM using enzyme-linked immune sorbent assay (ELISA). Result: Of the control group, 9/10 (9.9%) were seropositive for CMV IgG and 1/10 (1.09%) were sero positive for IgM. Also, all cancer groups demonstrated presence of IgG antibody classes as: The percentage of positive results in prostate, breast cancer and leukemia were 35.8 %, 37.2%, and 35.3% respectively. Conclusion: There was no significant correlation between leukemia, breast, prostate and HCMV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cytomegalovirus" title="cytomegalovirus">cytomegalovirus</a>, <a href="https://publications.waset.org/abstracts/search?q=serodiagnostic" title=" serodiagnostic"> serodiagnostic</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a> </p> <a href="https://publications.waset.org/abstracts/57018/serological-screening-of-cytomegalovirus-infection-among-sudanese-patients-with-leukemia-breast-and-prostate-cancers-at-radiation-isotope-center-in-khartoum" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/57018.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">386</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2817</span> Determination of Prostate Specific Membrane Antigen (PSMA) Based on Combination of Nanocomposite Fe3O4@Ag@JB303 and Magnetically Assisted Surface Enhanced Raman Spectroscopy (MA-SERS)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zuzana%20Chaloupkov%C3%A1">Zuzana Chaloupková</a>, <a href="https://publications.waset.org/abstracts/search?q=Zde%C5%88ka%20Markov%C3%A1"> Zdeňka Marková</a>, <a href="https://publications.waset.org/abstracts/search?q=V%C3%A1clav%20Ranc"> Václav Ranc</a>, <a href="https://publications.waset.org/abstracts/search?q=Radek%20Zbo%C5%99il"> Radek Zbořil</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate cancer is now one of the most serious oncological diseases in men with an incidence higher than that of all other solid tumors combined. Diagnosis of prostate cancer usually involves detection of related genes or detection of marker proteins, such as PSA. One of the new potential markers is PSMA (prostate specific membrane antigen). PSMA is a unique membrane bound glycoprotein, which is considerably overexpressed on prostate cancer as well as neovasculature of most of the solid tumors. Commonly applied methods for a detection of proteins include techniques based on immunochemical approaches, including ELISA and RIA. Magnetically assisted surface enhanced Raman spectroscopy (MA-SERS) can be considered as an interesting alternative to generally accepted approaches. This work describes a utilization of MA-SERS in a detection of PSMA in human blood. This analytical platform is based on magnetic nanocomposites Fe3O4@Ag, functionalized by a low-molecular selector labeled as JB303. The system allows isolating the marker from the complex sample using application of magnetic force. Detection of PSMA is than performed by SERS effect given by a presence of silver nanoparticles. This system allowed us to analyze PSMA in clinical samples with limits of detection lower than 1 ng/mL. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=diagnosis" title="diagnosis">diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=PSMA" title=" PSMA"> PSMA</a>, <a href="https://publications.waset.org/abstracts/search?q=MA-SERS" title=" MA-SERS"> MA-SERS</a>, <a href="https://publications.waset.org/abstracts/search?q=Ag%20nanoparticles" title=" Ag nanoparticles"> Ag nanoparticles</a> </p> <a href="https://publications.waset.org/abstracts/41975/determination-of-prostate-specific-membrane-antigen-psma-based-on-combination-of-nanocomposite-fe3o4-at-ag-at-jb303-and-magnetically-assisted-surface-enhanced-raman-spectroscopy-ma-sers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/41975.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">231</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2816</span> Application of Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) Database in Nursing Health Problems with Prostate Cancer-a Pilot Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hung%20Lin-Zin">Hung Lin-Zin</a>, <a href="https://publications.waset.org/abstracts/search?q=Lai%20Mei-Yen"> Lai Mei-Yen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate cancer is the most commonly diagnosed male cancer in the U.S. The prevalence is around 1 in 8. The etiology of prostate cancer is still unknown, but some predisposing factors, such as age, black race, family history, and obesity, may increase the risk of the disease. In 2020, a total of 7,178 Taiwanese people were nearly diagnosed with prostate cancer, accounting for 5.88% of all cancer cases, and the incidence rate ranked fifth among men. In that year, the total number of deaths from prostate cancer was 1,730, accounting for 3.45% of all cancer deaths, and the death rate ranked 6th among men, accounting for 94.34% of the cases of male reproductive organs. Looking for domestic and foreign literature on the use of OMOP (Observational Medical Outcomes Partnership, hereinafter referred to as OMOP) database analysis, there are currently nearly a hundred literature published related to nursing-related health problems and nursing measures built in the OMOP general data model database of medical institutions are extremely rare. The OMOP common data model construction analysis platform is a system developed by the FDA in 2007, using a common data model (common data model, CDM) to analyze and monitor healthcare data. It is important to build up relevant nursing information from the OMOP- CDM database to assist our daily practice. Therefore, we choose prostate cancer patients who are our popular care objects and use the OMOP- CDM database to explore the common associated health problems. With the assistance of OMOP-CDM database analysis, we can expect early diagnosis and prevention of prostate cancer patients' comorbidities to improve patient care. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=OMOP" title="OMOP">OMOP</a>, <a href="https://publications.waset.org/abstracts/search?q=nursing%20diagnosis" title=" nursing diagnosis"> nursing diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=health%20problem" title=" health problem"> health problem</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/181571/application-of-observational-medical-outcomes-partnership-common-data-model-omop-cdm-database-in-nursing-health-problems-with-prostate-cancer-a-pilot-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/181571.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">73</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2815</span> A Longitudinal Examination of the Impact of Treatment Modality on Relationship Satisfaction and Mental Health Quality of Life Outcomes among Prostate Cancer Survivors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Gabriela%20Ilie">Gabriela Ilie</a>, <a href="https://publications.waset.org/abstracts/search?q=Robert%20D.%20H.%20Rutledge"> Robert D. H. Rutledge</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A review of the literature reveals a need for longitudinal studies to properly understand the quality of life of prostate cancer survivors during their prostate cancer journey in order to identify opportunities for patient support and care during prostate cancer survivorship. In this study, mental health and relationship satisfaction were assessed longitudinally and by treatment modality among a population-based sample of Canadian adult men with a history of prostate cancer diagnosis. A total of 98 men, aged 51 or older with a history of prostate cancer completed an on-line 15-minute survey between May 2017 and February 2018, assessing mental health (Kessler Psychological Distress Scale) and relationship satisfaction (Dyadic Adjustment Scale) at baseline and at three months post-treatment with either active or nonactive prostate cancer treatment. Almost 1 in 6 men in this sample screened positive for mental health issues (17.34%, n=17) irrespective of treatment modality and most (n=11) were not currently on medication for depression, anxiety or both. Mental health outcomes were poorer for men with multimorbidity. For every instance of screening positive for mental health issues, 2.021 (95% CI:1.1 to 3.8) times more comorbidities were recorded. Relationship satisfaction and dyadic cohesion were statistically significantly lower from first assessment to 3 months for men who underwent multiple treatment modalities (surgery and radiation with hormonal therapy). Relationship satisfaction was also lower at 3 months for men who underwent radiation therapy. Almost 1 in 2 men in this sample (74%) indicated they did not attend a prostate cancer support group. Results suggest that treatment for mental health is underutilized in men with prostate cancer. Men who undergo multiple forms of active treatment appear more vulnerable to relationship dissatisfaction and feeling disconnected from their partner. Data points to important opportunities for patient education and care support during survivorship. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20survivorship" title="prostate cancer survivorship">prostate cancer survivorship</a>, <a href="https://publications.waset.org/abstracts/search?q=mental%20health" title=" mental health"> mental health</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20of%20life" title=" quality of life"> quality of life</a>, <a href="https://publications.waset.org/abstracts/search?q=relationship%20satisfaction" title=" relationship satisfaction"> relationship satisfaction</a> </p> <a href="https://publications.waset.org/abstracts/103928/a-longitudinal-examination-of-the-impact-of-treatment-modality-on-relationship-satisfaction-and-mental-health-quality-of-life-outcomes-among-prostate-cancer-survivors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/103928.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">117</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2814</span> Influence of Pretreatment Magnetic Resonance Imaging on Local Therapy Decisions in Intermediate-Risk Prostate Cancer Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Christian%20Skowronski">Christian Skowronski</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrew%20Shanholtzer"> Andrew Shanholtzer</a>, <a href="https://publications.waset.org/abstracts/search?q=Brent%20Yelton"> Brent Yelton</a>, <a href="https://publications.waset.org/abstracts/search?q=Muayad%20Almahariq"> Muayad Almahariq</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniel%20J.%20Krauss"> Daniel J. Krauss</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate cancer has the third highest incidence rate and is the second leading cause of cancer death for men in the United States. Of the diagnostic tools available for intermediate-risk prostate cancer, magnetic resonance imaging (MRI) provides superior soft tissue delineation serving as a valuable tool for both diagnosis and treatment planning. Currently, there is minimal data regarding the practical utility of MRI for evaluation of intermediate-risk prostate cancer. As such, the National Comprehensive Cancer Network’s guidelines indicate MRI as optional in intermediate-risk prostate cancer evaluation. This project aims to elucidate whether MRI affects radiation treatment decisions for intermediate-risk prostate cancer. This was a retrospective study evaluating 210 patients with intermediate-risk prostate cancer, treated with definitive radiotherapy at our institution between 2019-2020. NCCN risk stratification criteria were used to define intermediate-risk prostate cancer. Patients were divided into two groups: those with pretreatment prostate MRI, and those without pretreatment prostate MRI. We compared the use of external beam radiotherapy, brachytherapy alone, brachytherapy boost, and androgen depravation therapy between the two groups. Inverse probability of treatment weighting was used to match the two groups for age, comorbidity index, American Urologic Association symptoms index, pretreatment PSA, grade group, and percent core involvement on prostate biopsy. Wilcoxon Rank Sum and Chi-squared tests were used to compare continuous and categorical variables. Of the patients who met the study’s eligibility criteria, 133 had a prostate MRI and 77 did not. Following propensity matching, there were no differences between baseline characteristics between the two groups. There were no statistically significant differences in treatments pursued between the two groups: 42% vs 47% were treated with brachytherapy alone, 40% vs 42% were treated with external beam radiotherapy alone, 18% vs 12% were treated with external beam radiotherapy with a brachytherapy boost, and 24% vs 17% received androgen deprivation therapy in the non-MRI and MRI groups, respectively. This analysis suggests that pretreatment MRI does not significantly impact radiation therapy or androgen deprivation therapy decisions in patients with intermediate-risk prostate cancer. Obtaining a pretreatment prostate MRI should be used judiciously and pursued only to answer a specific question, for which the answer is likely to impact treatment decision. Further follow up is needed to correlate MRI findings with their impacts on specific oncologic outcomes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=magnetic%20resonance%20imaging" title="magnetic resonance imaging">magnetic resonance imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=definitive%20radiotherapy" title=" definitive radiotherapy"> definitive radiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=gleason%20score%207" title=" gleason score 7"> gleason score 7</a> </p> <a href="https://publications.waset.org/abstracts/153388/influence-of-pretreatment-magnetic-resonance-imaging-on-local-therapy-decisions-in-intermediate-risk-prostate-cancer-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153388.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">92</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2813</span> Anti-Prostate Cancer Effect of GV-1001, a Novel Gonadotropin-Releasing Hormone Receptor Ligand</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ji%20Won%20Kim">Ji Won Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Moo%20Yeol%20Lee"> Moo Yeol Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Keon%20Wook%20Kang"> Keon Wook Kang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> GV-1001, 16 amino acid fragment of human telomerase reverse transcriptase catalytic subunit (hTERT), has been developed as an injectable cancer vaccine for many types of solid tumors showing high-level of telomerase activity. In the present study, we evaluated the anti-cancer effect of GV-1001 on androgen-receptor-positive prostate cancer. Two signaling pathways, Gs-adenylate cyclase-cAMP and Gq-IP3-Ca2+ pathways play a central role in GnRH receptor (GnRHR)-mediated activities. We found that leuprolide acetate (LA) mainly acted on Gq-mediated Ca2+ signaling, while GV-1001 preferentially acted on cAMP signaling; and both the effects were counteracted by cetrorelix, a GnRHR antagonist. We further tested whether GV-1001 affects tumor growth of human prostate cancer cells in vivo. Prostate tumor xenografts were established using LNCap, androgen receptor-positive prostate cancer cells, and the nude mice bearing tumors were subcutaneously injected with GV-1001 (0.01, 0.1, 1, 10 microg/kg/day) and LA (0.01 microg/kg/day) for 2 weeks. GV-1001 (1 and 10 microg/kg/day) significantly inhibited tumor growth of LNCap xenografts. Interestingly, mRNA expression of MMP2 and MMP9 was significantly suppressed by GV-1001 injection, but not by LA administration. Boyden chamber assay revealed that GV-1001 potently inhibited cell migration of LNCap. Our finding suggests that GV-1001 as a novel GnRHR ligand, has anti-proliferative and anti-migratory effects on androgen receptor-positive prostate cancer cells. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=GV-1001" title="GV-1001">GV-1001</a>, <a href="https://publications.waset.org/abstracts/search?q=GnRH" title=" GnRH"> GnRH</a>, <a href="https://publications.waset.org/abstracts/search?q=hTERT" title=" hTERT"> hTERT</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/22012/anti-prostate-cancer-effect-of-gv-1001-a-novel-gonadotropin-releasing-hormone-receptor-ligand" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/22012.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">372</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2812</span> Assessment of Knowledge, Practices, and Attitudes Toward Prostate Cancer and Its Screening Among Men Aged 40 Years and Older in the United Arab Emirates: A Cross-Sectional Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahmoud%20Eladl">Mahmoud Eladl</a>, <a href="https://publications.waset.org/abstracts/search?q=Bahaaeldeen%20Hesham"> Bahaaeldeen Hesham</a>, <a href="https://publications.waset.org/abstracts/search?q=Saryia%20Adra"> Saryia Adra</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmad%20Addasi"> Ahmad Addasi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Al%20Tahawi"> Mohammad Al Tahawi</a>, <a href="https://publications.waset.org/abstracts/search?q=Musa%E2%80%99Ab%20Omair"> Musa’Ab Omair</a>, <a href="https://publications.waset.org/abstracts/search?q=Nafe%20Alhariri"> Nafe Alhariri</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Eladl"> Mohamed Eladl</a>, <a href="https://publications.waset.org/abstracts/search?q=Hiba%20J.%20Barqawi"> Hiba J. Barqawi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Prostate cancer is the second most common cancer in men globally and the fifth greatest cause of cancer-related mortality. In the United Arab Emirates (UAE), prostate cancer has been on the rise due to population aging. However, knowledge deficits and screening barriers do exist because of cultural, social, and psychological factors. The objective of this study is to assess the knowledge, practices, and attitudes of prostate cancer and its screening among men aged 40 years and above in the UAE. Methodology: A cross-sectional study was conducted between September 5 and October 31, 2024, using a self-administered online questionnaire distributed through social media platforms. Data collected from the questionnaire were analyzed using SPSS version 26 (IBM Corp., Armonk, NY). Results: A total of 471 responses were analyzed. The median age of participants was 51 ± 12. Most of the respondents were non-healthcare workers with at least a bachelor's degree. Most of the participants were moderately aware of prostate cancer risk factors and symptoms. However, there was a severe lack of awareness of genetic predisposition and racial risk factors. While 80.3% of participants were aware of the role of prostate-specific antigen tests in prostate screening, 62.8% recognized the role of a digital rectal examination. The most important barriers to screening were lack of perceived risk, time constraints, and fear of diagnosis. Conclusion: Significant knowledge gaps and barriers to prostate screening exist. Health education initiatives targeting cultural stigma with the use of culturally appropriate and accurate information through credible online platforms are necessary. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=male%20health%20awareness" title="male health awareness">male health awareness</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=PSA" title=" PSA"> PSA</a>, <a href="https://publications.waset.org/abstracts/search?q=screening" title=" screening"> screening</a>, <a href="https://publications.waset.org/abstracts/search?q=UAE" title=" UAE"> UAE</a> </p> <a href="https://publications.waset.org/abstracts/196126/assessment-of-knowledge-practices-and-attitudes-toward-prostate-cancer-and-its-screening-among-men-aged-40-years-and-older-in-the-united-arab-emirates-a-cross-sectional-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/196126.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">12</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2811</span> The Impact of a Prior Haemophilus influenzae Infection in the Incidence of Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Maximiliano%20Guerra">Maximiliano Guerra</a>, <a href="https://publications.waset.org/abstracts/search?q=Lexi%20Frankel"> Lexi Frankel</a>, <a href="https://publications.waset.org/abstracts/search?q=Amalia%20D.%20Ardeljan"> Amalia D. Ardeljan</a>, <a href="https://publications.waset.org/abstracts/search?q=Sarah%20Ghali"> Sarah Ghali</a>, <a href="https://publications.waset.org/abstracts/search?q=Diya%20Kohli"> Diya Kohli</a>, <a href="https://publications.waset.org/abstracts/search?q=Omar%20M.%20Rashid."> Omar M. Rashid.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction/Background: Haemophilus influenzae is present as a commensal organism in the nasopharynx of most healthy adults from where it can spread to cause both systemic and respiratory tract infection. Pathogenic properties of this bacterium as well as defects in host defense may result in the spread of these bacteria throughout the body. This can result in a proinflammatory state and colonization particularly in the lungs. Recent studies have failed to determine a link between H. Influenzae colonization and prostate cancer, despite previous research demonstrating the presence of proinflammatory states in preneoplastic and neoplastic prostate lesions. Given these contradictory findings, the primary goal of this study was to evaluate the correlation between H. Influenzae infection and the incidence of prostate cancer. Methods: To evaluate the incidence of Haemophilus influenzae infection and the development of prostate cancer in the future we used data provided by a Health Insurance Portability and Accountability Act (HIPAA) compliant national database. We were afforded access to this database by Holy Cross Health, Fort Lauderdale for the express purpose of academic research. Standard statistical methods were employed in this study including Pearson’s chi-square tests. Results: Between January 2010 and December 2019, the query was analyzed and resulted in 13, 691 patients in both the control and C. difficile infected groups, respectively. The two groups were matched by age range and CCI score. In the Haemophilus influenzae infected group, the incidence of prostate cancer was 1.46%, while the incidence of the prostate cancer control group was 4.56%. The observed difference in cancer incidence was determined to be a statistically significant p-value (< 2.2x10^-16). This suggests that patients with a history of C. difficile have less risk of developing prostate cancer (OR 0.425, 95% CI: 0.382 - 0.472). Treatment bias was considered, the data was analyzed and resulted in two groups matched groups of 3,208 patients in both the infected with H. Influenzae treated group and the control who used the same medications for a different cause. Patients infected with H. Influenzae and treated had an incidence of prostate cancer of 2.49% whereas the control group incidence of prostate cancer was 4.92% with a p-value (< 2.2x10^-16) OR 0.455 CI 95% (0.526 -0.754), proving that the initial results were not due to the use of medications. Conclusion: The findings of our study reveal a statistically significant correlation between H. Influenzae infection and a decreased incidence of prostate cancer. Our findings suggest that prior infection with H. Influenzae may confer some degree of protection to patients and reduce their risk for developing prostate cancer. Future research is recommended to further characterize the potential role of Haemophilus influenzae in the pathogenesis of prostate cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Haemophilus%20Influenzae" title="Haemophilus Influenzae">Haemophilus Influenzae</a>, <a href="https://publications.waset.org/abstracts/search?q=incidence" title=" incidence"> incidence</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=risk." title=" risk."> risk.</a> </p> <a href="https://publications.waset.org/abstracts/140196/the-impact-of-a-prior-haemophilus-influenzae-infection-in-the-incidence-of-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140196.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">198</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2810</span> Plasma Selenium Concentration and Polymorphism of Selenoprotein and Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yu-Mei%20Hsueh">Yu-Mei Hsueh</a>, <a href="https://publications.waset.org/abstracts/search?q=Cheng-Shiuan%20Tsai"> Cheng-Shiuan Tsai</a>, <a href="https://publications.waset.org/abstracts/search?q=Chao-Yuan%20Huang"> Chao-Yuan Huang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate Cancer (PC) is a malignant tumor originated in prostate and is a second common male’s cancer in the world. Incidence of PC in Asia countries, have still been rising over the past few decades. As an antioxidant, selenium can slow down prostate cancer tumor progression, but the association between plasma selenium levels and risk of aggressive prostate cancer may be modified by different genotype of selenoprotein. The aim of this study is to determine the relationship between plasma selenium, polymorphism of selenoprotein, urinaty total arsenic, and prostate cancer. Two hundred ninety five pathologically-confirmed cases of PC and 295 cancer-free controls were individually matched to case subjects by age (± 5 years) were recruited from Department of Urology of National Taiwan University Hospital, Taipei Municipal Wan Fang Hospital and Taipei Medical University Hospital. Personal interview and biospeciment of urine and blood collection from participants were conducted by well-trained interviewers after participants’ informed consent was obtained. Plasma selenium was measured by an inductively coupled plasma mass. Urinary arsenic concentration was detected using high-performance liquid chromatography-linked hydride generator and atomic absorption spectrometry. The polymorphism of SEPP1rs3797310 and SEP15 rs5859 were determined using polymerase chain reaction-restriction fragment length polymorphism method. The higher plasma selenium was the lower OR of PC with a dose-response relationship. Prostate cancer patients with high plasma selenium had low tumor stage and grade. Participants carried SEPP1rs3797310 CT+TT genotype compared to those with CC genotype had a lower OR of PC in crude model; then this relationship was disappeared after confounder was adjusted. Prostate cancer patients with high urinary total arsenic concentration had high tumor stage and grade. Urinary total arsenic concentration was significantly positively related with plasma selenium and prostate specific antigen concentration. Participants with lower plasma selenium concentration and higher urinary total arsenic concentration compared to those with higher plasma selenium concentration and lower urinary total arsenic concentration had a higher OR of PC with a dose-response relationship. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title="prostate cancer">prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=plasma%20selenium%20concentration" title=" plasma selenium concentration"> plasma selenium concentration</a>, <a href="https://publications.waset.org/abstracts/search?q=urinary%20arsenic%20concentration" title=" urinary arsenic concentration"> urinary arsenic concentration</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20specific%20antigen" title=" prostate specific antigen"> prostate specific antigen</a> </p> <a href="https://publications.waset.org/abstracts/23679/plasma-selenium-concentration-and-polymorphism-of-selenoprotein-and-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23679.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">472</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2809</span> MicroRNA Drivers of Resistance to Androgen Deprivation Therapy in Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Philippa%20Saunders">Philippa Saunders</a>, <a href="https://publications.waset.org/abstracts/search?q=Claire%20Fletcher"> Claire Fletcher</a> </p> <p class="card-text"><strong>Abstract:</strong></p> INTRODUCTION: Prostate cancer is the most prevalent malignancy affecting Western males. It is initially an androgen-dependent disease: androgens bind to the androgen receptor and drive the expression of genes that promote proliferation and evasion of apoptosis. Despite reduced androgen dependence in advanced prostate cancer, androgen receptor signaling remains a key driver of growth. Androgen deprivation therapy (ADT) is, therefore, a first-line treatment approach and works well initially, but resistance inevitably develops. Abiraterone and Enzalutamide are drugs widely used in ADT and are androgen synthesis and androgen receptor signaling inhibitors, respectively. The shortage of other treatment options means acquired resistance to these drugs is a major clinical problem. MicroRNAs (miRs) are important mediators of post-transcriptional gene regulation and show altered expression in cancer. Several have been linked to the development of resistance to ADT. Manipulation of such miRs may be a pathway to breakthrough treatments for advanced prostate cancer. This study aimed to validate ADT resistance-implicated miRs and their clinically relevant targets. MATERIAL AND METHOD: Small RNA-sequencing of Abiraterone- and Enzalutamide-resistant C42 prostate cancer cells identified subsets of miRs dysregulated as compared to parental cells. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was used to validate altered expression of candidate ADT resistance-implicated miRs 195-5p, 497-5p and 29a-5p in ADT-resistant and -responsive prostate cancer cell lines, patient-derived xenografts (PDXs) and primary prostate cancer explants. RESULTS AND DISCUSSION: This study suggests a possible role for miR-497-5p in the development of ADT resistance in prostate cancer. MiR-497-5p expression was increased in ADT-resistant versus ADT-responsive prostate cancer cells. Importantly, miR-497-5p expression was also increased in Enzalutamide-treated, castrated (ADT-mimicking) PDXs versus intact PDXs. MiR-195-5p was also elevated in ADT-resistant versus -responsive prostate cancer cells, while there was a drop in miR-29a-5p expression. Candidate clinically relevant targets of miR-497-5p in prostate cancer were identified by mining AGO-PAR-CLIP-seq data sets and may include AVL9 and FZD6. CONCLUSION: In summary, this study identified microRNAs that are implicated in prostate cancer resistance to androgen deprivation therapy and could represent novel therapeutic targets for advanced disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=microRNA" title="microRNA">microRNA</a>, <a href="https://publications.waset.org/abstracts/search?q=androgen%20deprivation%20therapy" title=" androgen deprivation therapy"> androgen deprivation therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=Enzalutamide" title=" Enzalutamide"> Enzalutamide</a>, <a href="https://publications.waset.org/abstracts/search?q=abiraterone" title=" abiraterone"> abiraterone</a>, <a href="https://publications.waset.org/abstracts/search?q=patient-derived%20xenograft" title=" patient-derived xenograft"> patient-derived xenograft</a> </p> <a href="https://publications.waset.org/abstracts/159310/microrna-drivers-of-resistance-to-androgen-deprivation-therapy-in-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/159310.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">145</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2808</span> ALDH1A1 as a Cancer Stem Cell Marker: Value of Immunohistochemical Expression in Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia, and Prostatic Adenocarcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20M.%20Abdelmoneim">H. M. Abdelmoneim</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20A.%20Babtain"> N. A. Babtain</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Barhamain"> A. S. Barhamain</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Z.%20Kufiah"> A. Z. Kufiah</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Malibari"> A. S. Malibari</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20F.%20Munassar"> S. F. Munassar</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20S.%20Rawa"> R. S. Rawa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Prostate cancer is one of the most common causes of morbidity and mortality in men in developed countries. Cancer Stem Cells (CSCs) could be responsible for the progression and relapse of cancer. Therefore, CSCs markers could provide a prognostic strategy for human malignancies. Aldehyde dehydrogenase 1A1 (ALDH1A1) activity has been shown to be associated with tumorigenesis and proposed to represent a functional marker for tumor initiating cells in various tumor types including prostate cancer. Material & Methods: We analyzed the immunohistochemical expression of ALDH1A1 in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma and assessed their significant correlations in 50 TURP sections. They were microscopically interpreted and the results were correlated with histopathological types and tumor grade. Results: In different prostatic histopathological lesions we found that ALDH1A1 expression was low in BPH (13.3%) and PIN (6.7%) and then its expression increased with prostatic adenocarcinoma (40%), and this was statistically highly significant (P value = 0.02). However, in different grades of prostatic adenocarcinoma we found that the higher the Gleason grade the higher the expression for ALDH1A1 and this was statistically significant (P value = 0.02). We compared the expression of ALDH1A1 in PIN and prostatic adenocarcinoma. ALDH1A1 expression was decreased in PIN and highly expressed in prostatic adenocarcinoma and this was statistically significant (P value = 0.04). Conclusion: Increasing ALDH1A1 expression is correlated with aggressive behavior of the tumor. Immunohistochemical expression of ALDH1A1 might provide a potential approach to study tumorigenesis and progression of primary prostate carcinoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ALDH1A1" title="ALDH1A1">ALDH1A1</a>, <a href="https://publications.waset.org/abstracts/search?q=BPH" title=" BPH"> BPH</a>, <a href="https://publications.waset.org/abstracts/search?q=PIN" title=" PIN"> PIN</a>, <a href="https://publications.waset.org/abstracts/search?q=prostatic%20adenocarcinoma" title=" prostatic adenocarcinoma"> prostatic adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/43391/aldh1a1-as-a-cancer-stem-cell-marker-value-of-immunohistochemical-expression-in-benign-prostatic-hyperplasia-prostatic-intraepithelial-neoplasia-and-prostatic-adenocarcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43391.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">262</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2807</span> Micro-Ribonucleic Acid-21 as High Potential Prostate Cancer Biomarker</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Regina%20R.%20Gunawan">Regina R. Gunawan</a>, <a href="https://publications.waset.org/abstracts/search?q=Indwiani%20Astuti"> Indwiani Astuti</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Raden%20Danarto"> H. Raden Danarto</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer is the leading cause of death worldwide. Cancer is caused by mutations that alter the function of normal human genes and give rise to cancer genes. MicroRNA (miRNA) is a small non-coding RNA that regulates the gen through complementary bond towards mRNA target and cause mRNA degradation. miRNA works by either promoting or suppressing cell proliferation. miRNA level expression in cancer may offer another value of miRNA as a biomarker in cancer diagnostic. miRNA-21 is believed to have a role in carcinogenesis by enhancing proliferation, anti-apoptosis, cell cycle progression and invasion of tumor cells. Hsa-miR-21-5p marker has been identified in Prostate Cancer (PCa) and Benign Prostatic Hyperplasia (BPH) patient’s urine. This research planned to explore the diagnostic performance of miR-21 to differentiate PCa and BPH patients. In this study, urine samples were collected from 20 PCa patients and 20 BPH patients. miR-21 relative expression against the reference gene was analyzed and compared between the two. miRNA expression was analyzed using the comparative quantification method to find the fold change. miR-21 validity in identifying PCa patients was performed by quantifying the sensitivity and specificity with the contingency table. miR-21 relative expression against miR-16 in PCa patient and in BPH patient has 12,98 differences in fold change. From a contingency table of Cq expression of miR-21 in identifying PCa patients from BPH patient, Cq miR-21 has 100% sensitivity and 75% specificity. miR-21 relative expression can be used in discriminating PCa from BPH by using a urine sample. Furthermore, the expression of miR-21 has higher sensitivity compared to PSA (Prostate specific antigen), therefore miR-21 has a high potential to be analyzed and developed more. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=benign%20prostate%20hyperplasia" title="benign prostate hyperplasia">benign prostate hyperplasia</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarker" title=" biomarker"> biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=miRNA-21" title=" miRNA-21"> miRNA-21</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/120043/micro-ribonucleic-acid-21-as-high-potential-prostate-cancer-biomarker" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/120043.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">159</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2806</span> Risk of Androgen Deprivation Therapy-Induced Metabolic Syndrome-Related Complications for Prostate Cancer in Taiwan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Olivia%20Rachel%20Hwang">Olivia Rachel Hwang</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu-Hsuan%20Joni%20Shao"> Yu-Hsuan Joni Shao</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Androgen Deprivation Therapy (ADT) has been a primary treatment for patients with advanced prostate cancer. However, it is associated with numerous adverse effects related to Metabolic Syndrome (MetS), including hypertension, diabetes, hyperlipidaemia, heart diseases and ischemic strokes. However, complications associated with ADT for prostate cancer in Taiwan is not well documented. The purpose of this study is to utilize the data from NHIRD (National Health Insurance Research Database) to examine the trajectory changes of MetS-related complications in men receiving ADT. The risks of developing complications after the treatment were analyzed with multivariate Cox regression model. Covariates including in the model were the complications before the diagnosis of prostate cancer, the age, and the year at cancer diagnosis. A total number of 17268 patients from 1997-2013 were included in this study. The exclusion criteria were patients with any other types of cancer or with the existing MetS-related complications. Changes in MetS-related complications were observed among two treatment groups: 1) ADT (n=9042), and 2) non-ADT (n=8226). The ADT group appeared to have an increased risk in hypertension (hazard ratio 1.08, 95% confidence interval 1.03-1.13, P = 0.001) and hyperlipidemia (hazard ratio 1.09, 95% confidence interval 1.01-1.17, P = 0.02) when compared with non-ADT group in the multivariate Cox regression analyses. In the risk of diabetes, heart diseases, and ischemic strokes, ADT group appeared to have an increased but not significant hazard ratio. In conclusion, ADT was associated with an increased risk in hypertension and hyperlipidemia in prostate cancer patients in Taiwan. The risk of hypertension and hyperlipidemia should be considered while deciding on ADT, especially those with the known history of hypertension and hyperlipidemia. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=androgen%20deprivation%20therapy" title="androgen deprivation therapy">androgen deprivation therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=ADT" title=" ADT"> ADT</a>, <a href="https://publications.waset.org/abstracts/search?q=complications" title=" complications"> complications</a>, <a href="https://publications.waset.org/abstracts/search?q=metabolic%20syndrome" title=" metabolic syndrome"> metabolic syndrome</a>, <a href="https://publications.waset.org/abstracts/search?q=MetS" title=" MetS"> MetS</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/70075/risk-of-androgen-deprivation-therapy-induced-metabolic-syndrome-related-complications-for-prostate-cancer-in-taiwan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/70075.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">289</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2805</span> Posttraumatic Stress Disorder and Associated Factors among Patients with Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Meral%20Huri">Meral Huri</a>, <a href="https://publications.waset.org/abstracts/search?q=Sedef%20%C5%9Eahin"> Sedef Şahin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Post-traumatic stress disorder (PTSD) is characterized by psychiatric symptoms and triggered by a terrifying experience which may immediately effect cognitive, affective, behavioral and social skills of the individual. One of the most common noncutaneous cancer among men is prostate cancer. The incidence of psychological stress is quite common in men with prostate cancer. The aim of the study was to explore the PTSD frequency among prostate cancer and define the relationship between occupational participation, coping skills and level of perceived social support among patients with prostate cancer. Forty patients diagnosed with prostate cancer were included in the study. After dividing the patients into two groups ( study/ control) according to type of tumor, we recorded their characteristics and evaluations differences. We evaluated the demographic information form, Structured Clinical Interview for DSM-IV (SCID- I)- Clinical Version for PTSD, Multidimensional Scale of Perceived Social Support, Styles of Coping Inventory and Canadian Occupational Performance Measure (COPM) before and after 1 month from surgery. The mean age of the study group (n:18) was 65.85.6 years (range: 61-79 years). The mean age of the control group (n: 22) was a little bit higher than the study group with mean age 71.3±6.9 years (range: 60-85 years). There was no statistically significant difference between the groups for age and the other characteristics. According to the results of the study, statistically significant difference was found between the level of PTSD of study and the control group. 22% of study group showed PTSD while 13% of the control group showed PTSD (r: 0.02, p<0.001). The scores of study group and control group showed statistically significant difference in five sub-categories of Styles of Coping Inventory. Patients with prostate cancer showed decreased scores in optimistic, seeking social supports and self-confident approach, while increased scores in helpless and submissive sub-categories than the control group (p<0.001). The scores of Multidimensional Scale of Perceived Social Supports of study group and control group showed statistically significant difference. The total perceived social supports score of the study group was 71.34 ± 0.75 while it was 75.34 ± 0.64 for the control group. Total and the sub-category scores of study group were statistically significant lower than the control group. According to COPM, mean scores of occupational participation of study group for occupational performance were 4.32±2.24 and 7.01±1.52 for the control group, respectively). Mean Satisfaction scores were 3,22±2.31 and 7.45±1.74 for the study and control group, respectively. The patients with prostate cancer and benign prostate hyperplasia (BPH) did not show any statistically difference in activity performance (r:0.87) while patients with prostate cancer showed statistically lower scores than the patients with BPH in activity satisfaction (r:0.02, p<0.001).Psycho-social occupational therapy interventions might help to decrease the prevalence of PTSD by increasing associated factors such as the social support perception, using coping skills and activity participation of patients with prostate cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=activity%20performance" title="activity performance">activity performance</a>, <a href="https://publications.waset.org/abstracts/search?q=occupational%20therapy" title=" occupational therapy"> occupational therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=posttraumatic%20stress%20disorder" title=" posttraumatic stress disorder"> posttraumatic stress disorder</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/77009/posttraumatic-stress-disorder-and-associated-factors-among-patients-with-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/77009.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">145</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2804</span> Toxicities associated with EBRT and Brachytherapy for Intermediate and High Risk Prostate Cancer, Correlated with Intra-operative Dosing</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rebecca%20Dunne">Rebecca Dunne</a>, <a href="https://publications.waset.org/abstracts/search?q=Cormac%20Small"> Cormac Small</a>, <a href="https://publications.waset.org/abstracts/search?q=Geraldine%20O%27Boyle"> Geraldine O'Boyle</a>, <a href="https://publications.waset.org/abstracts/search?q=Nazir%20Ibrahim"> Nazir Ibrahim</a>, <a href="https://publications.waset.org/abstracts/search?q=Anisha"> Anisha</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prostate cancer is the most common cancer among men, excluding non-melanoma skin cancers. It is estimated that approximately 12% of men will develop prostate cancer during their lifetime. Patients with intermediate, high risk, and very-high risk prostate cancer often undergo a combination of radiation treatments. These treatments include external beam radiotherapy with a low-dose rate or high-dose rate brachytherapy boost, often with concomitant androgen deprivation therapy. The literature on follow-up of patients that receive brachytherapy is scarce, particularly follow-up of patients that undergo high-dose rate brachytherapy. This retrospective study aims to investigate the biochemical failure and toxicities associated with triple therapy and external beam radiotherapy given in combination with brachytherapy. Reported toxicities and prostate specific antigen (PSA) were retrospectively evaluated in eighty patients that previously underwent external beam radiotherapy with a low-dose rate or high dose-rate brachytherapy boost. The severity of toxicities were correlated with intra-operative dosing during brachytherapy on ultrasound and CT scan. The results of this study will provide further information for clinicians and patients when considering treatment options. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=toxicities" title="toxicities">toxicities</a>, <a href="https://publications.waset.org/abstracts/search?q=combination" title=" combination"> combination</a>, <a href="https://publications.waset.org/abstracts/search?q=brachytherapy" title=" brachytherapy"> brachytherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=intra-operative%20dosing" title=" intra-operative dosing"> intra-operative dosing</a>, <a href="https://publications.waset.org/abstracts/search?q=biochemical%20failure" title=" biochemical failure"> biochemical failure</a> </p> <a href="https://publications.waset.org/abstracts/140057/toxicities-associated-with-ebrt-and-brachytherapy-for-intermediate-and-high-risk-prostate-cancer-correlated-with-intra-operative-dosing" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140057.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">245</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2803</span> The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Simin%20Shahvazi">Simin Shahvazi</a>, <a href="https://publications.waset.org/abstracts/search?q=Sepideh%20Soltani"> Sepideh Soltani</a>, <a href="https://publications.waset.org/abstracts/search?q=Seyed%20Mehdi%20Ahmadi"> Seyed Mehdi Ahmadi</a>, <a href="https://publications.waset.org/abstracts/search?q=Russell%20J.%20De%20Souza"> Russell J. De Souza</a>, <a href="https://publications.waset.org/abstracts/search?q=Amin%20Salehi-Abargouei"> Amin Salehi-Abargouei</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objectives: Vitamin D has received attention for its potential to disrupt cancer processes such as attenuating cell proliferation and exacerbating differentiation and apoptosis. However, whether there exists a role for vitamin D in the treatment of prostate cancer specifically remains controversial. We systematically review the literature to assess whether supplementation with vitamin D influences PSA response and overall survival in patients with prostate cancer. Methods: We searched PubMed, Scopus, ISI Web of Science and Google scholar from inception through up to 10 September 2017 for both before-and-after and randomized trials that evaluated the effect of vitamin D supplementation on the prostate specific antigen (PSA) response rate in participants with prostate cancer. The DerSimonian and Laird, inverse-weighted random-effects model was used to pool effect estimates from the studies. Heterogeneity and potential publication bias were evaluated. Subgroup analyses were also performed. Results: Twenty-two studies (16 before-after and 6 randomized controlled trials) were found and included in meta-analysis. The analysis on controlled clinical trials revealed that PSA change from baseline [weighted mean difference (WMD) = -1.66 ng/ml, 95%CI: -0.69, 0.36, P= 0.543)], PSA response (RR=1.18, 95%CI: 0.97, 1.45, P=0.104) and mortality rate (risk ratio (RR) = 1.05, 95% CI: 0.81-1.36; P=0.713) was not significantly different between vitamin D supplementation and placebo groups. Single arm trials revealed that vitamin D supplementation had had a modest effect on PSA response rate: 19% of those enrolled had at least a 50% reduction in PSA by the end of treatment (95% CI: 7% to 31%; p=0.002). Conclusion: We found that vitamin D modestly increases the PSA response rate in single arm studies. No effect on serum PSA levels, PSA response and mortality was seen in randomized controlled clinical trials. It does not seem patients with prostate cancer benefit from vitamin D supplementation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=mortality" title="mortality">mortality</a>, <a href="https://publications.waset.org/abstracts/search?q=prostatic%20neoplasms" title=" prostatic neoplasms"> prostatic neoplasms</a>, <a href="https://publications.waset.org/abstracts/search?q=PSA%20response" title=" PSA response"> PSA response</a>, <a href="https://publications.waset.org/abstracts/search?q=vitamin%20D" title=" vitamin D"> vitamin D</a> </p> <a href="https://publications.waset.org/abstracts/100491/the-effect-of-vitamin-d-supplementation-on-prostate-cancer-a-systematic-review-and-meta-analysis-of-clinical-trials" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/100491.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">196</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2802</span> Development of Lectin-Based Biosensor for Glycoprofiling of Clinical Samples: Focus on Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Dominika%20Pihikova">Dominika Pihikova</a>, <a href="https://publications.waset.org/abstracts/search?q=Stefan%20Belicky"> Stefan Belicky</a>, <a href="https://publications.waset.org/abstracts/search?q=Tomas%20Bertok"> Tomas Bertok</a>, <a href="https://publications.waset.org/abstracts/search?q=Roman%20Sokol"> Roman Sokol</a>, <a href="https://publications.waset.org/abstracts/search?q=Petra%20Kubanikova"> Petra Kubanikova</a>, <a href="https://publications.waset.org/abstracts/search?q=Jan%20Tkac"> Jan Tkac</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Since aberrant glycosylation is frequently accompanied by both physiological and pathological processes in a human body (cancer, AIDS, inflammatory diseases, etc.), the analysis of tumor-associated glycan patterns have a great potential for the development of novel diagnostic approaches. Moreover, altered glycoforms may assist as a suitable tool for the specificity and sensitivity enhancement in early-stage prostate cancer diagnosis. In this paper we discuss the construction and optimization of ultrasensitive sandwich biosensor platform employing lectin as glycan-binding protein. We focus on the immunoassay development, reduction of non-specific interactions and final glycoprofiling of human serum samples including both prostate cancer (PCa) patients and healthy controls. The fabricated biosensor was measured by label-free electrochemical impedance spectroscopy (EIS) with further lectin microarray verification. Furthermore, we analyzed different biosensor interfaces with atomic force microscopy (AFM) in nanomechanical mapping mode showing a significant differences in the altitude. These preliminary results revealing an elevated content of α-2,3 linked sialic acid in PCa patients comparing with healthy controls. All these experiments are important step towards development of point-of-care devices and discovery of novel glyco-biomarkers applicable in cancer diagnosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biosensor" title="biosensor">biosensor</a>, <a href="https://publications.waset.org/abstracts/search?q=glycan" title=" glycan"> glycan</a>, <a href="https://publications.waset.org/abstracts/search?q=lectin" title=" lectin"> lectin</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a> </p> <a href="https://publications.waset.org/abstracts/33642/development-of-lectin-based-biosensor-for-glycoprofiling-of-clinical-samples-focus-on-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/33642.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">373</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2801</span> Local Availability Influences Choice of Radical Treatment for Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jemini%20Vyas">Jemini Vyas</a>, <a href="https://publications.waset.org/abstracts/search?q=Oluwatobi%20Adeyoe"> Oluwatobi Adeyoe</a>, <a href="https://publications.waset.org/abstracts/search?q=Jenny%20Branagan"> Jenny Branagan</a>, <a href="https://publications.waset.org/abstracts/search?q=Chandran%20Tanabalan"> Chandran Tanabalan</a>, <a href="https://publications.waset.org/abstracts/search?q=Aakash%20Pai"> Aakash Pai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Radical prostatectomy and radiotherapy are both viable options for the treatment of localised prostate cancer. Over the years medicine has evolved towards a patient-centred approach. Patient decision-making is not motivated by clinical outcomes alone. Geographical location and ease of access to treating clinician are contributory factors. With the development of robotic surgery, prostatectomy has been centralised into tertiary centres. This has impacted on the distances that patients and their families are expected to travel. Methods: A single centre retrospective study was undertaken over a five-year period. All patients with localised prostate cancer, undergoing radical radiotherapy or prostatectomy were collected pre-centralisation. This was compared to the total number undergoing these treatments post centralisation. Results: Pre-centralisation, both radiotherapy and prostatectomy groups had to travel a median of less than five miles for treatment. Post-centralisation of pelvic surgery, prostatectomy patients had to travel a median of more than 40 miles, whilst travel distance for the radiotherapy group was unchanged. In the post centralisation cohort, there was a 63% decline in the number of patients undergoing radical prostatectomy per month from a mean of 5.1 to 1.9. The radical radiotherapy group had a concurrent 41% increase in patient numbers with a mean increase from 13.3 to 18.8 patients per month. Conclusion: Choice of radical treatment in localised prostate cancer is based on multiple factors. This study infers that local availability can influence choice of radical treatment. It is imperative that efforts are made to maintain accessibility to all viable options for prostate cancer patients, so that patient choice is not compromised. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate" title="prostate">prostate</a>, <a href="https://publications.waset.org/abstracts/search?q=prostatectomy" title=" prostatectomy"> prostatectomy</a>, <a href="https://publications.waset.org/abstracts/search?q=radiotherapy" title=" radiotherapy"> radiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=centralisation" title=" centralisation"> centralisation</a> </p> <a href="https://publications.waset.org/abstracts/157692/local-availability-influences-choice-of-radical-treatment-for-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157692.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">96</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2800</span> Concordance between Biparametric MRI and Radical Prostatectomy Specimen in the Detection of Clinically Significant Prostate Cancer and Staging</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rammah%20Abdlbagi">Rammah Abdlbagi</a>, <a href="https://publications.waset.org/abstracts/search?q=Egmen%20Tazcan"> Egmen Tazcan</a>, <a href="https://publications.waset.org/abstracts/search?q=Kiriti%20Tripathi"> Kiriti Tripathi</a>, <a href="https://publications.waset.org/abstracts/search?q=Vinayagam%20Sudhakar"> Vinayagam Sudhakar</a>, <a href="https://publications.waset.org/abstracts/search?q=Thomas%20Swallow"> Thomas Swallow</a>, <a href="https://publications.waset.org/abstracts/search?q=Aakash%20Pai"> Aakash Pai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction and Objectives: MRI has an increasing role in the diagnosis and staging of prostate cancer. Multiparametric MRI includes multiple sequences, including T2 weighting, diffusion weighting, and dynamic contrast enhancement (DCE). Administration of DCE is expensive, time-consuming, and requires medical supervision due to the risk of anaphylaxis. Biparametric MRI (bpMRI), without DCE, overcomes many of these issues; however, there is conflicting data on its accuracy. Furthermore, data on the concordance between bpMRI lesion and pathology specimen, as well as the rates of cancer stage upgrading after surgery, is limited within the available literature. This study aims to examine the diagnostic test accuracy of bpMRI in the diagnosis of prostate cancer and radiological assessment of prostate cancer staging. Specifically, we aimed to evaluate the ability of bpMRI to accurately localise malignant lesions to better understand its accuracy and application in MRI-targeted biopsies. Materials and Methods: One hundred and forty patients who underwent bpMRI prior to radical prostatectomy (RP) were retrospectively reviewed from a single institution. Histological grade from the prostate biopsy was compared with surgical specimens from RP. Clinically significant prostate cancer (csPCa) was defined as Gleason grade group ≥2. bpMRI staging was compared with RP histology. Results: Overall sensitivity of bpMRI in diagnosing csPCa independent of location and staging was 98.87%. Of the 140 patients, 29 (20.71%) had their prostate biopsy histology upgraded at RP. 61 (43.57%) patients had csPca noted on RP specimens in areas that were not identified on the bpMRI. 55 (39.29%) had upstaging after RP from the original staging with bpMRI. Conclusions: Whilst the overall sensitivity of bpMRI in predicting any clinically significant cancer was good, there was notably poor concordance in the location of the tumour between bpMRI and eventual RP specimen. The results suggest that caution should be exercised when using bpMRI for targeted prostate biopsies and validates the continued role of systemic biopsies. Furthermore, a significant number of patients were upstaged at RP from their original staging with bpMRI. Based on these findings, bpMRI results should be interpreted with caution and can underestimate TNM stage, requiring careful consideration of treatment strategy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biparametric%20MRI" title="biparametric MRI">biparametric MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=Ca%20prostate" title=" Ca prostate"> Ca prostate</a>, <a href="https://publications.waset.org/abstracts/search?q=staging" title=" staging"> staging</a>, <a href="https://publications.waset.org/abstracts/search?q=post%20prostatectomy%20histology" title=" post prostatectomy histology"> post prostatectomy histology</a> </p> <a href="https://publications.waset.org/abstracts/157550/concordance-between-biparametric-mri-and-radical-prostatectomy-specimen-in-the-detection-of-clinically-significant-prostate-cancer-and-staging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157550.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">70</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2799</span> The Superiority of 18F-Sodium Fluoride PET/CT for Detecting Bone Metastases in Comparison with Other Bone Diagnostic Imaging Modalities</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mojtaba%20Mirmontazemi">Mojtaba Mirmontazemi</a>, <a href="https://publications.waset.org/abstracts/search?q=Habibollah%20Dadgar"> Habibollah Dadgar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bone is the most common metastasis site in some advanced malignancies, such as prostate and breast cancer. Bone metastasis generally indicates fewer prognostic factors in these patients. Different radiological and molecular imaging modalities are used for detecting bone lesions. Molecular imaging including computed tomography, magnetic resonance imaging, planar bone scintigraphy, single-photon emission tomography, and positron emission tomography as noninvasive visualization of the biological occurrences has the potential to exact examination, characterization, risk stratification and comprehension of human being diseases. Also, it is potent to straightly visualize targets, specify clearly cellular pathways and provide precision medicine for molecular targeted therapies. These advantages contribute implement personalized treatment for each patient. Currently, NaF PET/CT has significantly replaced standard bone scintigraphy for the detection of bone metastases. On one hand, 68Ga-PSMA PET/CT has gained high attention for accurate staging of primary prostate cancer and restaging after biochemical recurrence. On the other hand, FDG PET/CT is not commonly used in osseous metastases of prostate and breast cancer as well as its usage is limited to staging patients with aggressive primary tumors or localizing the site of disease. In this article, we examine current studies about FDG, NaF, and PSMA PET/CT images in bone metastases diagnostic utility and assess response to treatment in patients with breast and prostate cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=skeletal%20metastases" title="skeletal metastases">skeletal metastases</a>, <a href="https://publications.waset.org/abstracts/search?q=fluorodeoxyglucose" title=" fluorodeoxyglucose"> fluorodeoxyglucose</a>, <a href="https://publications.waset.org/abstracts/search?q=sodium%20fluoride" title=" sodium fluoride"> sodium fluoride</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20imaging" title=" molecular imaging"> molecular imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=precision%20medicine" title=" precision medicine"> precision medicine</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20%2868Ga-PSMA-11%29" title=" prostate cancer (68Ga-PSMA-11)"> prostate cancer (68Ga-PSMA-11)</a> </p> <a href="https://publications.waset.org/abstracts/120469/the-superiority-of-18f-sodium-fluoride-petct-for-detecting-bone-metastases-in-comparison-with-other-bone-diagnostic-imaging-modalities" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/120469.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">110</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2798</span> Pathological Disparities in Patients Diagnosed with Prostate Imaging Reporting and Data System 3 Lesions: A Retrospective Study in a High-Volume Academic Center</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Reza%20Roshandel">M. Reza Roshandel</a>, <a href="https://publications.waset.org/abstracts/search?q=Tannaz%20Aghaei%20Badr"> Tannaz Aghaei Badr</a>, <a href="https://publications.waset.org/abstracts/search?q=Batoul%20Khoundabi"> Batoul Khoundabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Sara%20C.%20Lewis"> Sara C. Lewis</a>, <a href="https://publications.waset.org/abstracts/search?q=Soroush%20Rais-Bahrami"> Soroush Rais-Bahrami</a>, <a href="https://publications.waset.org/abstracts/search?q=John%20Sfakianos"> John Sfakianos</a>, <a href="https://publications.waset.org/abstracts/search?q=Reza%20Mehrazin"> Reza Mehrazin</a>, <a href="https://publications.waset.org/abstracts/search?q=Ash%20K.%20Tewari"> Ash K. Tewari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Prostate biopsy is the most reliable diagnostic method for choosing the appropriate management of prostate cancer. However, discrepancies between Gleason grade groups (GG) of different biopsies remain a significant concern. This study aims to assess the association of the radiological factors with GG discrepancies in patients with index Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, using radical prostatectomy (RP) specimens as the most accurate and informative pathology. Methods: This single-institutional retrospective study was performed on a total of 2289 consecutive prostate cancer patients with combined targeted and systematic prostate biopsy followed by radical prostatectomy (RP). The database was explored for patients with the index PI-RADS 3 lesions version 2 and 2.1. Cancers with PI-RADS 4 or 5 scoring were excluded from the study. Patient characteristics and radiologic features were analyzed by multivariable logistic regression. Number-density of lesions was defined as the number of lesions per prostatic volume. Results: Of the 151 prostate cancer cases with PI-RADS 3 index lesions, 27% and 17% had upgrades and downgrades at RP, respectively. Analysis of grade changes showed no significant associations between discrepancies and the number or the number density of PI-RADS 3 lesions. Moreover, the study showed no significant association of the GG changes with race, age, location of the lesions, or prostate volume. Conclusions: This study demonstrated that in PI-RADS 3 cancerous nodules, the chance of the pathology changes in the final pathology of RP specimens was low. Furthermore, having multiple PI-RADS 3 nodules did not change the conclusion, as the possibility of grade changes in patients with multiple nodules was similar to those with solitary lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prostate" title="prostate">prostate</a>, <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma" title=" adenocarcinoma"> adenocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=multiparametric%20MRI" title=" multiparametric MRI"> multiparametric MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=Gleason%20score" title=" Gleason score"> Gleason score</a>, <a href="https://publications.waset.org/abstracts/search?q=robot-assisted%20surgery" title=" robot-assisted surgery"> robot-assisted surgery</a> </p> <a href="https://publications.waset.org/abstracts/161253/pathological-disparities-in-patients-diagnosed-with-prostate-imaging-reporting-and-data-system-3-lesions-a-retrospective-study-in-a-high-volume-academic-center" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/161253.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">134</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=94">94</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=95">95</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=prostate%20cancer%20markers&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>